One of neurologist Anelyssa D’Abreu’s least favorite tasks is giving her patients a dreaded diagnosis: early-stage Alzheimer’s disease. But it’s not quite as bad as it used to be. Today when they ask, “Is there anything we can do?” D’Abreu has a new answer: “Perhaps.” Unlike a decade ago, when D’Abreu had little to offer her patients with Alzheimer’s, there …
Read More »Controversial New Alzheimer’s Drugs Offer Hope—But at a High Cost
